Researching Ebola in Africa: The Partnership for Research on Ebola Virus in Liberia (PREVAIL)

Share this page:

Title

Researching Ebola in Africa: The Partnership for Research on Ebola Virus in Liberia (PREVAIL)

Subject

Description

The 2014-2016 Ebola outbreak in West Africa was the largest in history, with nearly 28,700 cases and more than 11,300 deaths. As local and international healthcare workers responded to the outbreak, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Ministry of Health in Liberia—one of the hardest-hit countries—established PREVAIL, or the Partnership for Research on Ebola Virus in Liberia. Specifically, the partnership was quickly formed in 2014 in response to a request from the Liberian Minister of Health to the U.S. Secretary of Health and Human Services. Since then PREVAIL has conducted biomedical research according to rigorous international standards to advance Ebola science and to improve the health of people in Liberia and around the world. Collaborative teams of Liberian and NIAID investigators have launched multiple clinical studies to evaluate candidate Ebola treatments and vaccines, and to better understand the long-term health effects of Ebola in those who survive the disease. The PREVAIL clinical research agenda is also expanding beyond Ebola research to address additional health needs of the Liberian people. (NIH)

Date Last Updated (Year-Month-Day)

2019-01-04